CICLESONIDE IN TREATMENT OF CHILDHOOD BRONCHIAL ASTHMA
https://doi.org/10.15690/vsp.v12i1.567
Abstract
The review of clinical trials, confirming high efficacy and safety of new inhalation glucocorticoid based on ciclesonide in treatment of childhood bronchial asthma is shown in this article. Ciclesonide is an extra-fine dispersed glucocorticoid with high pulmonary bioavailability (52%), 55% of it is distributed through peripheral respiratory tract, which plays significant role in development and clinical course of asthma. High anti-inflammatory activity, minimal systemic and local side effects and one-time administration per day make this drug usage preferable in pediatric practice.
About the Authors
K. E. Efendieva
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First State Medical University,
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First State Medical University;
The Russian National Research Medical University named after N.I. Pirogov, Moscow,
Russian Federation
Russian Federation
Yu. G. Levina
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First State Medical University
Russian Federation
Russian Federation
E. A. Vishneva
Scientific Centre of Children Health, Moscow,
Russian Federation
Russian Federation
A. A. Alekseeva
Scientific Centre of Children Health, Moscow;
I.M. Sechenov First State Medical University
Russian Federation
Russian Federation
E. G. Bokuchava
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
References
1. Report Global Strategy for Asthma Management and Prevention. GINA. 2011.//www.ginasthma.org.
2. Namazova-Baranova L. S. Allergiya u detei: ot teorii — k praktike. [Allergy in children: from theory to practice]. Chapter VIII. Moscow. 2010–2011. Pp. 268–474.
3. Efendiyeva K. E. Influence of different methods of treatment on a quality of life in children with bronchial asthma. Author’s abstract of doctoral thesis. Moscow. 2005. 107 pp.
4. Halterman J. S., Yoos H. L., Conn K. M. et al. The impact of childhood asthma on parental quality of life. J. Asthma. 2004; 41: 645–653.
5. Baranov A. A., Khaitov R. M. Allergology and immunology. Clinical recommendations for pediatricians. Moscow. 2011. Pp. 123–124.
6. Brand P. L., Carroll W., Wildhaber J. H. Parent and child perceptions on the impact of asthma: global results from the «Room to Breathe» survey. Eur. Respir. Society electronic abstract book. 2009; 785: abs 4438.
7. Barnes P. J., Pedersen S., Busse W. W. Efficacy and safety of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 1998; 157: 51–53.
8. Derendorf H. Pharmacokinetic and pharmacodinamic properties of inhaled corticosteroids in relation to efficacy and safery. Respir. Med. 1997; 91 (Suppl. A): 22–28.
9. Dietzel K., Engelstatter R., Keller A. Ciclesonide: an on-siteactivated steroid. Prog. Respir. Res. 2001; 31:91–93.
10. Hubner M., Hochhaus G., Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol. Allergy Clin. North Am. 2005; 25: 469–488.
11. Derendorf H., Nave R., Drollmann A., Cerasol F., Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28: 1042–1050.
12. Nave R., Meyer W., Fuhst R., Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther. 2005; 18 (6): 390–396.
13. Allen D. B. Growth supression by glucocorticoid therapy. Endocrinol. Metabol. Clin. North. Am. 1996 (25): 699–717.
14. Levina Yu. G. Clinical-immunological efficacy and safety of combined drugs in treatment of bronchial asthma in children. Author’s abstract of doctoral thesis. Moscow. 2005. 143 pp.
15. Bisgaard H. Delivery of inhaled medication to children. J. Asthma. 1997; 34: 443–467.
16. Lindstroem M. Particles in small airways: mechanisms for deposition and clearance. Thesis, Stockholm: Karolinska Institute. 2004. 52 p.
17. Schuepp K. G., Jauernig J., Janssens H. M. et al. In vitro determination of the optimal particle size for nebulised aerosol delivery to infants. J. Aerosol. Med. 2005; 18 (2): 225–235.
18. Nenasheva N. M. Ciclesonide (Alvesko) — a new inhalation corticosteroid for treatment of bronchial asthma. Effective pharmacotherapy. 2012; 2: pp. 3–14.
19. Torrego Fernandez A., Munoz Cano R. M. Clinical relevance of distal airway involvement in asthma. Arch. Bronconeumol. 2011; 47 (Suppl. 2): 17–19.
20. van den Berge M., Ten Hacken N. H., van der Wiel E., Postma D. S. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy. 2013; 68 (1): 16–26.
21. Gelfand E. W., Georgitis J. W., Noonan M., Ruff M. E. Once-daily ciclesonide in children: efficacy and safety in asthma. J. Pediatr. 2006; 148: 377–383.
22. Pedersen S., Potter P., Dachev S., Bosheva M., Kaczmarek J., Springer E., Dunkel J., Engelstatter R. Respir. Med. 2010; 104: 1618–1628.
23. von Berg A., Engelstatter R., Minic P., Sreckovic M., Gar cia M. L. G., Latos T., Vermeulen J. H., Leichtl S., Hellbardt S., Bethke T. D. Com parison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr. Allergy Immunol. 2007; 18: 391–400.
24. Skoner D. P., Maspero J., Banerji D. and Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008; 121: 1–14.
Review
For citations:
Efendieva K.E., Namazova-Baranova L.S., Levina Yu.G., Vishneva E.A., Alekseeva A.A., Bokuchava E.G. CICLESONIDE IN TREATMENT OF CHILDHOOD BRONCHIAL ASTHMA. Current Pediatrics. 2013;12(1):117-122. (In Russ.) https://doi.org/10.15690/vsp.v12i1.567
Views:
1002
Email this article 
